Tally clinical trial -cognitive impairment

About the investigational drug

The TALLY clinical trial aims to understand if an investigational drug could be safe and potentially effective in impacting CIAS.

This potential treatment is a positive allosteric modulator (potentiator) of the AMPA receptor that represents a mechanistically novel approach to the treatment of CIAS.

In an early study involving a small number of patients, it showed a potential to impact cognitive function in patients with CIAS.

This topic was automatically closed 90 days after the last reply. New replies are no longer allowed.